AIVITA Biomedical’s Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival
Personalized cancer vaccine reduces risk of disease progression or death by 38% IRVINE, Calif., Nov. 17, 2020 /PRNewswire/ — AIVITA Biomedical, Inc., a private biotechnology company specializing in innovative stem cell applications, today announced data from its multi-center Phase 2 clinical trial of its personalized cancer vaccine, AV-GBM-1, in patients with newly diagnosed glioblastoma (GBM). The … Continued